Lumida
/SNDX
⌘K
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX
$22.80USD+0.40%+0.09 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$22 – $23

52W RANGE

$9
$26

AI Summary

Stalk
StalkMedium

SNDX is in a Stage 2 advance with a bullish medium-term tradable side, evidenced by sustained higher highs and lows and price holding above the 50DMA. A recent pullback into the short EMAs and 50DMA on light volume shows constructive consolidation rather than exhaustion, suggesting a favorable entry zone on a further shallow retracement into the EMA support area.

  • Q1 revenue of $64.9M (+224% YoY) led by Revuforge net sales of $48.9M (+144% YoY)
  • Approximately 330 new patients started Revuforge therapy in Q1, underlining adoption momentum
  • Negative profitability metrics and poor earnings yield suggest valuation risks
Full analysis →
Insider Trades19 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 8, 2026SellSNDXMichael A MetzgerChief Executive Officer64,750$15.31$2.0B-10.90%+148.91%$991.3K+0.00%10b5-1Buy Now
Jun 11, 2026SellSNDXNicholas A.J. BotwoodHead of R&D, CMO119,265$16.15$2.0B-10.90%+148.91%$1.9M-3.67%10b5-1Buy Now
Jun 1, 2026SellSNDXKeith A. GoldanChief Financial Officer1,177$18.99$2.0B-10.90%+148.91%$22.4K-0.84%Buy Now
Jun 1, 2026SellSNDXMichael A MetzgerChief Executive Officer6,847$18.99$2.0B-10.90%+148.91%$130.0K-1.39%Buy Now
Feb 9, 2026SellSNDXKeith A. GoldanChief Financial Officer3,410$21.03$2.0B-10.90%+148.91%$71.7K-2.37%Buy Now
Feb 9, 2026SellSNDXMichael A MetzgerChief Executive Officer17,159$21.03$2.0B-10.90%+148.91%$360.8K-3.37%Buy Now
Feb 6, 2026SellSNDXKeith A. GoldanChief Financial Officer2,082$20.62$2.0B-10.90%+148.91%$42.9K-0.79%Buy Now
Feb 6, 2026SellSNDXMichael A MetzgerChief Executive Officer7,412$20.62$2.0B-10.90%+148.91%$152.8K-0.78%Buy Now
Dec 1, 2025SellSNDXKeith A. GoldanChief Financial Officer1,224$19.12$2.0B-10.90%+148.91%$23.4K-1.31%Buy Now
Sep 8, 2025SellSNDXMichael A MetzgerChief Executive Officer314,614$13.66$2.0B-10.90%+148.91%$4.3M+0.00%10b5-1Buy Now
Jul 16, 2025SellSNDXKeith A. GoldanChief Financial Officer1,296$9.29$2.0B-10.90%+148.91%$12.0K-1.38%Buy Now
Jul 16, 2025SellSNDXMichael A MetzgerChief Executive Officer7,534$9.29$2.0B-10.90%+148.91%$70.0K-2.46%Buy Now
May 16, 2025BuySNDXNicholas A.J. BotwoodHead of R&D, CMO11,765$8.99$2.0B-10.90%+148.91%$105.8K+50.28%Buy Now
Mar 14, 2025BuySNDXMichael A MetzgerChief Executive Officer6,074$7.20$2.0B-10.90%+148.91%$43.7K+2.02%Buy Now
Mar 4, 2025SellSNDXMichael A MetzgerChief Executive Officer15,628$11.12$2.0B-10.90%+148.91%$173.8K+0.00%10b5-1Buy Now
Feb 10, 2025SellSNDXKeith A. GoldanChief Financial Officer3,777$15.50$2.0B-10.90%+148.91%$58.6K-4.00%Buy Now
Feb 10, 2025SellSNDXNeil GallagherPresident, Head of R&D4,618$15.50$2.0B-10.90%+148.91%$71.6K-5.15%Buy Now
Feb 10, 2025SellSNDXMichael A MetzgerChief Executive Officer13,288$15.50$2.0B-10.90%+148.91%$206.0K-4.24%Buy Now
Jun 14, 2024BuySNDXKeith A. GoldanChief Financial Officer1,250$20.03$2.0B-10.90%+148.91%$25.0K+2.43%Buy Now